Detalhe da pesquisa
1.
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
N Engl J Med
; 2024 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38828951
2.
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 2024 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38832972
3.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(12): 1423-1433, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37944541
4.
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
Blood
; 137(9): 1154-1165, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33080623
5.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica
; 107(10): 2408-2417, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354247
6.
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
J Clin Oncol
; 41(21): 3689-3699, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279408
7.
Clinical Outcomes in Patients With COVID-19 and Hematologic Disease.
Clin Lymphoma Myeloma Leuk
; 23(8): 589-598, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37236904
8.
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
NEJM Evid
; 1(7): EVIDoa2200006, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319255
9.
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
J Clin Oncol
; 40(8): 855-865, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34910556
10.
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Leuk Res
; 104: 106576, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33839618
11.
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
J Thromb Haemost
; 18(10): 2672-2684, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32511880
12.
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Lancet Haematol
; 7(5): e370-e380, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32213342
13.
Wideband linear detector arrays for optoacoustic imaging based on polyvinylidene difluoride films.
J Biomed Opt
; 23(9): 1-5, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29790319
14.
Biochemical observation of the rapid mobility of nuclear HMGB1.
Biochim Biophys Acta
; 1729(1): 57-63, 2005 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-15823506